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Context: We studied two families from Galicia (northwest Spain) with Pendred syndrome (PS) and
unusual thyroid phenotypes. In family A, the proposita had a large goiter and hypothyroxinemia but
normal TSH and free T3 (FT3). In family B, some affected members showed deafness but not goiter.
Objective: Our objective was to identify the mutations causing PS and molecular mechanisms
underlying the thyroid phenotypes.
Interventions: Interventions included extraction of DNA and of thyroid tissue.
Patients: Propositi and 10 members of the two families participated in the study.
Main Outcome Measures: Main outcome measures included SLC26A4 gene analysis, deiodinase ac-
tivities in thyroid tissue, and c.416–1G3A effects on SLC26A4 splicing. In addition, a primary PS thy-
rocyte culture, T-PS2, was obtained from propositus B and compared with another culture of normal
human thyrocytes, NT, by Western blotting, confocal microscopy, and iodine uptake kinetics.
Results:PropositaAwasheterozygous for c.578C3Tandc.279delT,presentedwithgoiter, andhad
normal TSH and FT3 but low FT4 attributable to high type 1 and type 2 iodothyronine deiodinase
activities in the goiter. Propositus B bore c.279delT and a novel mutation c.416–1G3A; some deaf
relatives were homozygous for c.416–1G3A but did not present goiter. The c.279delT mutation
was associated with identical haplotype in the two families. T-PS2 showed truncated pendrin
retained intracellularly and high iodine uptake with low efflux leading to iodine retention.
Conclusions: c.279delT is a foundermutation inGalicia. PropositaAadapted topoororganification
by increasingdeiodinase activities in thegoiter, avoidinghypothyroidism. Lackofgoiter in subjects
homozygous for c.416–1G3A was due to incomplete penetrance allowing synthesis of some
wild-type pendrin. Intracellular iodine retention, as seen in T-PS2, could play a role in thyroid
alterations in PS. (J Clin Endocrinol Metab 93: 267–277, 2008)
Pendred syndrome (PS) is an autosomal recessive disordercharacterized by congenital sensorineural hearing loss and
goiter without or with hypothyroidism (1). SLC26A4 (solute
carrier family 26, member 4), the PS gene (2), encodes a trans-
membrane protein (pendrin) expressed in the thyroid gland, in-
ner ear, endometrium, and kidney, where it is involved in iodide,
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chloride, formate, andnitrate transport (3).SLC26A4mutations
arealsoimplicatedinneurosensorynonsyndromicrecessivedeafness4,
DFNB4, with inner earmalformations (4, 5). Around 150mutations
in SLC26A4 have been reported (http://www.medicine.uiowa.edu/
pendredandbor/listed_mutations.htm). Different populations
are affected by different mutations, and founder mutations have
been reported in a few cases (4–17).
In the thyroid gland, pendrin acts at the apical pole of thy-
rocytes to transport intracellular iodide into the follicular lumen
(18). Loss of pendrin function causes a failure in iodine supply
and an organification defect often leading to euthyroid goiters
(8, 10, 12, 16, 19) similar to those seen in iodine-deficient
areas (20).We report two unrelated families with PSwho have
a thymidine deletion c.279delT at exon 3, resulting from a
founder mutation. A thyrocyte cell line, T-PS2, was obtained
from a primary thyroid culture of the family B propositus,
providing data on the effects of the c.279delT and c.416–
1G3Amutations onmutated pendrin localization and iodine
handling in affected thyrocytes.
Subjects and Methods
Subjects
Family A
Thepropositawas a43-yr-old deafwomanwith grade III asymmetric
multinodular goiter (Fig. 1). Neither her parents nor her three siblings
were deaf. Although serum free T4 (FT4)was low (0.51 ng/dl, 6.56 pmol/
liter; normal range 0.85–1.69 ng/dl), her serum TSH, FT3, and rT3 were
normal; serum thyroglobulin (Tg) was 1312 ng/ml (normal range 0–80
ng/ml), anti-thyroperoxidase (anti-TPO) and anti-Tg antibodies were
negative, and urine iodine was 102 g/liter (median value for her age in
our population is 79.7 g/liter). A computer tomography scan showed
enlarged vestibular aqueducts. A perchlorate test showed an organifica-
tiondefect. Increasing daily doses of L-thyroxine (25, 50, 75, and100g)
were given, buther serumFT4 levels remained lowor low-normal.A total
thyroidectomywasperformed (Fig. 1), and thepatientwasdischargedon
100 g L-thyroxine daily.
Family B
The propositus, a 26-yr-old deaf male, was referred to us for hypo-
thyroidism. He was the only child of a nonconsanguineous deaf couple
A B
(stop)
wildtype
279delT
wildtype
mutant
C D
c. del279T c.578C>T
A B
FIG. 1. A, The proposita of family A, a 43-yr-old woman with deafness and a large goiter; B, gross appearance of thyroid at surgery showing multinodular goiter with
larger nodules in the right lobe; C and D, the proposita was compound heterozygous for c.279delT, a frameshift mutation at exon 3 (C), and c.578C3T at exon 5 (D).
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with a strong family history of deafness and goiter (Fig. 2). He had a
goiter with a 1-cm nodule in the right lobe. Serum TSHwas 7.08U/ml,
with low FT4 (0.73 ng/dl, 9.40 pmol/liter) and normal FT3. Anti-TPO
and -Tg antibodies were negative. A fine-needle aspiration cytology was
suggestive of follicular neoplasia, and a right hemithyroidectomy was
performed. The propositus’ mother had a grade II goiter, whereas his
father had neither goiter nor abnormal serum levels of thyroid hormone,
although a perchlorate test did showa partial organification defect. Both
parents presented with profound neonatal deafness, as did two of the
mother’s four siblings and two of the father’s seven siblings. One of the
father’s brothers (subject IIIB.3, Fig. 2) showedmuch less severe deafness
starting in childhood.
Genetic studies
Genomic DNA was extracted from blood cells of the propositi, 10
members of their families, and 50 normal volunteers (age range 20–60
yr) and from thyroid tissues of the propositi and 60 control subjects
(healthy parts of surgically removed multinodular goiters). All exons of
the SLC26A4 gene were amplified by PCR (primer sequences and PCR
conditions available upon request) and sequenced in anABIPRISM3100
(Applied Biosystems, Foster City, CA). The study was approved by our
Institutional Review Board, and informed consents were obtained.
For haplotype analysis, four polymorphic markers closely linked to
SLC26A4 were genotyped. According to the NCBI STS map,D7S2459
is located in SLC26A4 intron 10, and D7S2420 and D7S496 are prox-
imal and D7S2456 distal to SLC26A4. Oligonucleotide primer se-
quences were obtained from http://www.ncbi.nlm.nih.gov, and forward
primers were fluorescence labeled. PCR products were electrophoresed
in a MegaBace 500 (Amersham Pharmacia Biotech, Piscataway, NJ).
Alleles were numbered according to product size.
Effects of the intronic mutation on SLC26A4 were investigated in
skin fibroblasts and thyroid tissue from the B propositus. cDNA frag-
ments spanning from exon 3 to exon 6 were PCR amplified and cloned
into a pGEMT-Easy vector (Promega, Madison, WI), and the products
were sequenced as described.
Determination of type 1 and type 2 iodothyronine
deiodinases (D1 and D2) and MCT8
D1, D2, and MCT8 mRNA levels and D1 and D2 activities were
measured in thyroid tissue from the A proposita and from healthy parts
of six surgically derived thyroid specimens and two toxic follicular
adenomas.
MCT8, D1, and D2mRNAs and the internal control RNA polymer-
ase II were quantified in a Light Cycler 2.0 (Roche, Indianapolis, IN)
using specific probes and oligonucleotide primers designed by Universal
ProbeLibrary (Roche). Real-time PCR conditions are available upon re-
quest. Resultswere normalized forRNApolymerase II, using the 2CT
method (21).
D1 andD2 activitiesweremeasured in thyroid tissue homogenates as
described (22, 23).
Thyroid hormone levels in thyroid gland sampleswere determinedby
in-house RIAs (24).
FIG. 2. Top, Family pedigrees. Phenotypes are indicated within each symbol, and genotypes and results of thyroid function tests appear below each of the family
members studied. Abnormal values are in bold numbers. Roman numbers indicate family generation, and Arabic numbers indicate studied family members. Bottom,
Haplotypes. Carriers of c.279delT share a common haplotype not observed in noncarrier members, suggesting a founder effect. In family B, the novel mutation c.416–
1G3A was found in the propositus’ maternal grandfather, mother, father, and two paternal siblings. c.416–1G3A carrier and noncarrier members of family B share a
common haplotype not present in family A.
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Histological and immunohistochemical studies
Immunohistochemical studieswereperformedonparaffin sectionsof
thyroid specimens from the two propositi using an EnVision peroxidase/
diaminobenzidine kit with antibodies to thyroid transcription factor-1
(Dako, Carpinteria, CA; dilution 1:50), Tg (Tg6, 1:2000; Dako), TPO
(MoAb47, 1:50; Dako), calcitonin (polyclonal, 1:1000; BioGenex, San
Ramon, CA), cytokeratin (CK) 7 (OV-TL 12/30, 1:50; Dako), CK1–
CK8, CK10, CK13, CK14, CK16, and CK19 (AE1–AE3, 1:20; Dako),
CK20 (Ks 20.8, 1:20; Dako), vimentin (V9, 1:5000; BioGenex), and
galectin-3 (9C4, 1:200; Novocastra, Newcastle upon Tyne, UK). An
affinity-purifiedantibodyagainst pendrin, PS1Ab (1:20), recognizing the
first 15 amino acids of human pendrin, denominated pendrin1 (25), was
also used. Negative controls in which the primary antibodies were re-
placed by nonimmune mouse serum, and positive controls such as nor-
mal thyroid tissue fromautopsyand surgical thyroid tissue froma subject
with Graves’ disease, were included.
Cell culture, immunoblotting, and immunofluorescence
analysis
Thyrocyte cell lines from the B propositus thyroid gland (T-PS2),
from a normal thyroid tissue specimen (NT), and from a cold follicular
adenoma (T-FA6) were obtained as previously described (26).
Amounts of the sodium-iodide symporter (NIS) and pendrin were
estimated byWestern blot of protein extracts. Low-detergent extracts to
assess cytoplasmicmembrane contents [endoplasmic reticulum (ER) and
Golgi], and total extracts to include plasma membrane proteins, were
prepared as described (27, 28). Immunodetection was carried out with
antibodies toNIS (1:300;Chemicon,Temecula,CA), PS1Ab (1:300) and
tubulin (1:5000; SigmaChemical Co., St. Louis,MO). Bound antibodies
were detected with alkaline phosphatase-labeled secondary antibodies
(Tropix, Bedford, MA).
Immunofluorescence assays were done in cells seeded onto glass cover-
slips, fixedwith 1%paraformaldehyde for 20min, permeabilizedwith Tri-
ton 1% for 10 min at room temperature, and then quenched with 50 mM
NH4Cl for 1 h.Alternatively, cellswere fixedwith ice-coldmethanol for 10
min. Antibodies usedwere theChemicon anti-NIS (1:50) and PS1Ab (1:20,
methanol-fixed cells) or PS5Ab, which recognizes the last 13 carboxyl-ter-
minal amino acids of human pendrin, denominated pendrin5 (1:20, para-
formaldehyde-fixed cells) (25). Thyrocytes were identified by Tg immuno-
fluorescence (Novocastra; 1:65).Thenucleuswas counterstainedwith4,6-
diamidino-2-phenylindole (DAPI) (Sigma; 1:100).
Iodide uptake
Iodide uptake was measured according to Dohan et al. (29) with
minor modifications, using T-PS2 and NT cells grown in 24-well plates.
For steady-state experiments, incubations proceeded for 30min with 20
or 40 M Na125I. For time-course analysis, cells were incubated for 30
sec and 1, 2, 5, 10, 15, and 30 min. For dose-response experiments, cells
were incubated for 30 sec and 5, 30, and 60minwith 0.1, 0.25, 0.5, 1.25,
2.5, 5, 10, 20,or40MNaI.Cellswere lysedbyadding200l 1MNaOH
to each well for 10 min at room temperature. 125I in cells was then
quantitated in a -scintillation counter. Cells from replicate wells were
counted to express Iuptake as picomoles per 105 cells.NaClO4 (40M)
was added to inhibit I uptake when appropriate.
For efflux experiments, cells were loaded with 20 M Na125I for 30
min and washed (29); some replicates were terminated at this point
(intracellular 125I content 100%), whereas in the other replicates, the
mediumwas replaced at 5, 15, and 25min as described (29). Radioactive
medium was quantitated, and results are expressed as percentage of
intracellular content. Finally, cells were lysed for quantitation of 125I.
Kinetic curves were fitted by nonlinear least-square regression using
GraphPad Prism software based on the Michaelis-Menten equation. All
parameters were determined at least in triplicate in three independent
experiments.
TABLE 1. mRNA transcript analysis of cDNA from the family-B propositus
Allele
mRNA transcript
Expected proteinSize (bp) Mutation
r.279delT
1 499 r279delt Premature stop
r.416–1g3a
2 500 Normal splice (no mutation) Wild-type pendrin
3 499 Abnormal splice, 416_417del Premature stop
4 420 Abnormal splice, 416_495del Premature stop
5 417 Abnormal splice, 416_498del Premature stop
TABLE 2. Relative mRNA expression of deiodinases and MCT8, and deiodinase activities, in the family-A proposita and control
thyroid tissues.
Sample
Relative mRNA expression Enzymatic activity
MCT8 D1 D2 D1 (pmol/minmg protein) D2 (fmol/hmg protein)
Family A proposita 1.00  0.05 1.00  0.07 1.00  0.08 70.7  0.1 166.5  34.9
1 0.93  0.09 0.37  0.05a 0.54  0.10a 11.2  1.6a 86.3  18.8a
2 0.36  0.03a 0.11  0.01a 0.16  0.12a ND ND
3 0.45  0.02a 0.24  0.01a 0.21  0.03a 6.8  0.3a 32.5  5.3a
3T 0.99  0.20 0.64  0.11 0.29  0.06a 45.4  3.8a 132.9  12
4T 1.09  0.36 1.10  0.20 0.37  0.01a 142  4.3b 180  2
5 0.30  0.03a 0.26  0.02a 0.55  0.10a 24.7  4.3a 54.8  22.7a
6 1.63  0.04b 0.78  0.07 0.59  0.17 34.2  4.1a 150.7  0.6
7 0.91  0.01 0.55  0.22 0.18  0.14a ND ND
Data are shown as means  SD. Numbers 1–7 refer to healthy parts of surgically derived thyroid specimens. ND, Not done; T, thyroid tissue from inside a toxic
adenoma.
a P  0.05 vs. family-A proposita.
b P  0.05 vs. family-A proposita with higher values than the family-A proposita.
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Thyroid function tests
TSH,FT4, andFT3weremeasuredby chemiluminescenceusingADVIA
Centaur (BayerDiagnostics, Tarrytown,NY). Tg, TgAb, andTPOAbwere
measured using Immulite 2000 (Diagnostic Products Corp., Los Angeles,
CA). rT3 was measured by RIA (Biocode Hycel, Liege, Belgium).
Statistical analysis
One-way ANOVAwith post hoc comparisons by Student’s t test and
the Wilcoxon signed-rank test were used for statistical analysis.
Results
Genetic studies
The family-A proposita was heterozygous for c.279delT and
c.578C3T.Mutationc.279delT,athymidinedeletionlocatedinexon
3 (Fig. 1C), causes a frameshift that introduces a stop codon three
amino acids downstream (p.Ser93ArgfsX3).
Mutation c.578C3T (Fig. 1D), located in
exon 5, results in replacement of the normal
threonine with an isoleucine at codon 193
(p.Thr193Ile) in the thirdmembrane regionof
pendrin. The proposita inherited mutation
c.578C3T from her mother. No mutations
were found in the proposita’s sister, and no
DNA samples were available from her father
or two brothers.
The family B propositus was heterozygous
for c.279delT (see above) and for c.416–
1G3A, located at the acceptor splice site of in-
tron 4, leading to replacement of the normal
guanosine with an adenosine. His mother had
the same compound heterozygous genotype
(c.279delT, c.416–1G3A) and his father was
homozygousforc.416–1G3A(Fig.2).Twoof
the father’s siblings (IIIB.1 and IIIB.2, Fig. 2)
showed profound deafness and were homozy-
gous for c.416–1G3A. Subject IIIB.3 (Fig. 2)
did not have SLC26A4mutations and showed
much less severe deafness.
Mutations c.279delT, c.578C3T, and
c.416–1G3A were not found in 120 alleles
from60normal thyroidtissuesamplesobtained
fromGalician patients or in 100 alleles from50
blood samples obtained from normal Galician
volunteers aged between 20 and 60 yr.
Members of the two families bearing
c.279delT shared the same haplotype, which
was not present in unaffected individuals (Fig.
2).Regardingc.416–1G3A,bothaffectedand
unaffected members of family B share a com-
mon haplotype not found in family A (Fig. 2).
PCR amplification of propositus B thyroid
SLC26A4 cDNA, extending from exon 3 to
exon6,gave theexpected500-bpproductanda
420-bp product. A similar result was obtained
using fibroblast cDNA from this propositus. In
control thyroid tissue, only a 500-bp product
was observed. The 500-bp fragment corre-
sponded to three transcripts (Table 1): a 499-bp transcript [r.279delt
(37.5%)] resulting from thymidine deletion at nucleotide 279, a
499-bp transcript [r.416–1 g3a;416_417del (25%)] resulting
from an abnormal splicing one base from the regular splicing site,
and an unexpected 500-bp wild-type transcript (37.5%). The
420-bp fragment likewise corresponded to two transcripts, of 420
and417bp, thatresultedfromabnormalsplicing79and82bpfrom
the regular site (r.416–1 g3a; 416_495del, 416_498del). All the
abnormal transcripts introduced premature stop codons.
Deiodinase and MCT8 levels
Deiodinase mRNA expression and activities were higher in
the thyroid gland of theA proposita than inmost control thyroid
tissues (Table 2). MCT8 mRNA expression was also high in the
proposita’s thyroid (Table 2). Thyroid hormone contents in con-
FIG. 3. A, Gross appearance of right thyroid lobe from the propositus of family B; B and C, hematoxylin-
eosin stain of thyroid tissue from the propositi of family A (B) and family B (C); D and E, lack of apical
membrane staining for pendrin with PS1Ab, an antibody against the first 15 amino acids of human pendrin,
with perinuclear enhanced halo in thyroid follicle cells from the propositi of family A (D) and weak cytoplasmic
staining in family B (E); F, strong apical membrane PS1Ab staining is seen in Graves’ disease; G–I, Tg and TPO
immunoreactivity (inset) was found in both propositi and control thyroid glands: the proposita of family A (G),
the propositus of family B (H), and Graves’ disease (I). All original magnifications,200.
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FIG. 4. At the outer plasma membrane, normal thyrocytes (NT) express fully glycosylated NIS and pendrin, whereas cells from the propositus of family B (T-PS2) express
only NIS. A, The appearance of cultured NT (a) and T-PS2 cells (b) is similar under the phase-contrast microscope. The cells are small and polygonal and leave round
spaces between them, recalling a follicular structure (see arrows). In both cell lines, using DAPI for nuclear counterstaining, practically all cells expressed Tg (shown for
T-PS2, c and d). B, Western blotting against NIS (left) and pendrin (right) using hot SDS extracts enriched in plasma membrane proteins (membrane) or 1% Triton
extracts with intracellular membrane content, i.e. Golgi or ER (cytoplasmic). As a loading control, the membranes were rehybridized against tubulin. NIS is expressed
mainly as the 100-kDa fully glycosylated form at the plasma membrane in NT, T-PS2, and the T-FA6 primary-culture follicular adenoma line from our BANTTIC
collection; smaller bands around 80 kDa correspond to nonglycosylated immature NIS. Intracellular levels are undetectable in all lines except NT, in which a faint band
can be seen suggesting slightly greater NIS expression. Mouse 3T3 fibroblasts were used as negative control. NT cells express the 130-kDa fully glycosylated pendrin at
the plasma membrane, but only a very weak band (less than 5%) can be seen in T-PS2 and T-FA6 cells. The faint 85-kDa band is the nonglycosylated protein. In
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trol thyroid glandswere 2–160g/g forT4 and2–42g/g forT3.
In the proposita’s thyroid, T4 and T3 content was 0.09 and 0.05
g/g, respectively.
Histology and immunohistochemistry
Thyroid glands from the two propositi showed similar mi-
croscopic appearance (Fig. 3). The thyroid tissue and hyperplas-
tic nodules were hypercellular, with normal and microfollicular
areas along with some fibrous septae. Tall columnar cells in the
follicles and scattered cells with nuclear atypia, characterized by
enlargement and hyperchromasia, were also seen. Immunohis-
tochemical findings were likewise similar in the two propositi
(Fig. 3); follicular cells contained thyroid transcription factor-1,
Tg, TPO, CK (CK7, AE1–AE3), and vimentin andwere negative
for calcitonin, CK20, and galectin-3.
Follicles fromnormal thyroid gland and fromGraves’ disease
(Fig. 3F) showed pendrin1 immunoreactivity (PS1Ab) in the lu-
minal/apical border. Thyroid tissue from proposita B was neg-
ative at the apical membrane and weakly stained follicular cy-
toplasm (Fig. 3E), suggesting that truncated proteins fromalleles
c.279delT and c.416–1G3Awere either unstable or down-reg-
ulated. Thyroid tissue from proposita A was negative at the api-
cal membrane but presented a perinuclear enhanced halo (Fig.
3D), suggesting that full-length pendrin from allele c.578C3T
was stable although retained in intracellular perinuclear or-
ganelles (ER and Golgi).
Cell cultures, immunoblotting, and immunofluorescence
analysis
T-PS2, a thyrocyte cell line compound heterozygous for
c.279delTand c.416–1G3A,wasobtained froma thyroid spec-
imen of the B propositus and compared with a line of normal
human thyrocytes, NT, from our bank (BANTTIC) (26, 27).
Both cell lines have similar polygonal epithelial appearance,
making follicle-like rounded structures (see Fig. 4A, a and b).
More than 90%of the thyrocytes in both lines expressedTg (Fig.
4A, c and d). Doubling times were also similar (around 23 h).
The NT and T-PS2 cell lines showed similar levels of glyco-
sylated plasma-membraneNIS (Fig. 4B), higher thanT-FA6 cells
(Fig. 4B). NT cells showed high levels of glycosylated plasma-
membrane pendrin (around 130 kDa) and aweaker cytoplasmic
band corresponding topendrin in theprocess of sorting (Fig. 4B).
A smaller band around 85 kDa corresponds to nonglycosylated
immature pendrin. T-PS2 cells showed a very weak band of gly-
cosylated pendrin, in both membrane and cytoplasmic extracts,
suggesting intracellular retention of the scarce normal pendrin
(Fig. 4B). Negative control 3T3 mouse fibroblasts did not ex-
press pendrin, but a smaller band around 80 kDa was observed
(Fig. 4B). Interestingly, T-FA6 cells that expressed a faint band
at the plasmamembrane showed strong intracellular expression
of pendrin (Fig. 4B). The presence of a small quantity of normal
protein agrees with the results mentioned above on the effect of
c.416–1G3A on SLC26A4 splicing (see Table 1); as noted,
mutation c.416–1G3A showed incomplete penetrance leading
to a marked decrease but not complete disappearance of the
normal pendrin transcript.
Confocal immunofluorescence studies with PS1Ab showed
staining ofNT thyrocytes at a point near the nucleus in theGolgi
location and in narrow lines typical of plasma membrane local-
ization (Fig. 4C, e and f).Almost all T-PS2 thyrocytes showed the
spot near the nucleus (Fig. 4C, g and h), but no lines were de-
tected, indicating either that normal and truncated proteinswere
both retained in the Golgi or that the concentration of normal
pendrin is very low at the membrane. Recent results in our lab-
oratory have shown low levels of pendrin mRNA expression in
T-PS2 compared with NT (unpublished results), suggesting that
the weak membrane expression of pendrin in T-PS2 could be
related not only to defective membrane targeting but also to low
transcription levels of the pendrin mutants.
We also studied the colocalization of NIS and pendrin (using
PS1Abagainstpendrin1andPS5Abagainstpendrin5). Innormal
thyrocytes, bothNIS and pendrin1 showed a linear staining typ-
ical of plasma membrane localization (Fig. 4D, i–l). However,
the two proteins were usually not expressed in the same mem-
branepatches, as canbe seen fromthe scarce colocalization in the
projections and the z planes. In T-PS2 thyrocytes, NIS was also
located in the plasmamembrane, but pendrin1 showed very few
spots outside the Golgi (Fig. 4D, m–p). Next, we repeated the
colocalization studies using PS5Ab, recognizing the last 13 car-
boxyl-terminal amino acids of human pendrin. In these studies,
both NIS and pendrin showed linear staining in the NT thyro-
cytes, but again, each protein localized in its plasma membrane
region,with little colocalization (Fig. 4D,q–t).Although the cells
were grown in monolayers, this arrangement recalls that of par-
tially polarized thyrocytes. In the T-PS2 thyrocytes, despite the
correctly localizedmembraneNIS, onlyweakpendrin spotswere
seen (Fig. 4D, u–y).
Iodide uptake
NT cells showed fast iodide uptake, with cellular iodide con-
tent plateauing at 2 min and not changing over the remainder of
the 30-min experiment (Fig. 5A). Thekinetics curve suggests that
the two iodine transporters (NIS and pendrin) were working in
opposite directions. NIS initiates iodide uptake, and once intra-
intracellular membranes, NT cells express a weak band corresponding to pendrin in the process of sorting, and T-PS2 cells likewise show only a weak band. However,
T-FA6 cells retain pendrin intracellularly. C, Confocal immunofluorescence images using the same pendrin antibody as in B, PS1Ab (specific for the N-terminal part of
the protein). DAPI is used to show nuclei. Both a 40 water-immersion objective with 3 magnification (e and g) and a 63 oil-immersion objective with a 1.5
magnification (f and h) were used. PS1Ab staining is localized in the Golgi (round spots beside the nuclei) and the plasma membrane (straight lines indicated by arrows)
in normal thyrocytes (NT); in T-PS2 thyrocytes, pendrin appears to be retained in the Golgi (truncated proteins). D, Double immunofluorescence with NIS and PS1Ab
shows intracellular and plasma membrane staining (arrows) of both proteins in NT (i–l, 1000). Note that membrane colocalization is not frequent: the z projections
obtained through stacking of confocal images show that, although localized in the membrane, the two proteins rarely coincide in the same locations, as indicated by
the scarce yellow spots. T-PS2 cells (m–p, 1000) show intracellular and plasma membrane staining of NIS, but only one isolated spot of pendrin can be seen at the
plasma membrane, whereas the rest is retained in the Golgi. Similar double-immunofluorescence studies were performed using PS5Ab, specific for the C-terminal end
of the pendrin protein. Both NIS and pendrin are localized at the plasma membrane in NT cells (q–t, 1000), although both proteins seem to occupy different
membrane domains (see z projections). In T-PS2 cells, the PS5Ab image is overexposed to demonstrate the absence of specific staining (u–y).
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cellular iodide concentration reaches a certain level, pendrinwill
start efflux, maintaining the amount of iodide inside the thyro-
cyte at a constrained level. In contrast, T-PS2 cells showed a
progressive increase in iodide level, which plateaued at around
15 min (Fig. 5A), in accordance with a single transporter (NIS)
model. Vmax was two times higher in T-PS2 than NT cells,
suggesting that iodide was accumulated in T-PS2 thyrocytes. In
fact, the steady-state uptake after 30 min was higher in T-PS2
than NT thyrocytes (Fig. 5B).
Efflux was faster from NT than from T-PS2 cells (Fig. 5C,
left). At 5 min, 40% of radioactivity had already effluxed from
NT cells, but no significant efflux was seen from T-PS2; by 15
min, almost all radioactivity had effluxed from NT cells, but
40% remained in T-PS2. When residual iodide was measured at
the end of the experiment, T-PS2 cells maintained higher intra-
cellular iodide than NT cells (Fig. 5C, right).
Dose-response curves showed that after 5 min, T-PS2 cells had
already reached equilibrium for iodide uptake with a Michaelis-
Menten constant (Km) similar to that expected for NIS at equilib-
rium (22  4.8 M) (Fig. 6). In contrast, NT cells achieved equi-
libriumand the expectedKm for iodideuptakeat1h.Except at very
short times of incubation (30 sec), when Vmax was higher for NT
cells, the Vmax was twice as high in T-PS2 thyrocytes at any given
time.These results suggest that normal thyrocytes behave as a com-
plex system in which both transporters (NIS and pendrin) need to
reach equilibrium slowly and that intracellular iodide concentra-
tions are not high; however, PS-affected thyrocytes accumulate io-
dine through NIS, and iodine leaves the cell inefficiently through
other nonspecific transporters.
Discussion
Two Galician families with PS were studied. SLC26A4 gene se-
quences showed two previously described mutations, c.279delT
(8, 17) and c.578C3T (11, 16) and a novel mutation c.416–
1G3A. Both families had the c.279delT mutation, and a com-
mon haplotype was seen only in c.279delT carriers, suggesting a
founder effect for this mutation. Galicians have low genetic di-
versity in comparison with other European populations, and
founder effects are not uncommon (30).
The c.416–1G3A mutation was present in family B. Al-
though the parents denied that theywere related, theywere born
in the same village, and a common haplotype for c.416-G3A
was found in both affected and unaffected family Bmembers but
not in haplotyped members of family A. Until recently, the Gali-
cian population was organized in small and relatively isolated
groups, and it is likely that the parents of propositus B have a
common ancestor. The fact that this mutation has not been pre-
viously reported also suggests that c.416–1G3A originated in
Galicia.
Webelieve that thephenotypeof theAproposita (large goiter,
normal serumTSH and FT3, and hypothyroxinemia) is an adap-
tive response to poor organification. In experimental animals,
iodine-deficient diet increases thyroidweight and favors the syn-
thesis and secretion of T3 resulting in an increase in serum and
tissue T3/T4 ratio (31, 32). These changes are partially due to a
TSH-independent increase in T3 generation (32), which can lead
to low serumT4, with normal or slightly elevated T3 and normal
TSH (31). In our patient, due to the marked increase in thyroid
gland size, the raisedD1andD2 levelswere sufficient tomaintain
FIG. 5. T-PS2 thyrocytes take up iodide and retain it intracellularly. A, Time
course of iodide uptake (20 M NaI) by thyrocyte lines. Normal NT cells show fast
uptake in the first 30 sec, reaching a plateau at 2 min, with no further changes in
intracellular iodine content over the remainder of the 30-min experiment (r2 
0.65); the kinetic curve suggests that, during the first 2 min, NIS transports iodide
into NT thyrocytes but that iodide is then effluxed from the cells through
pendrin, with the two transporters (NIS and pendrin) then working in opposite
directions to maintain equilibrium. In contrast, T-PS2 cells show a progressive
increase in iodide uptake, reaching a plateau much later (r2  0.99), suggesting
a model with a single transporter (NIS); in fact, there were significant differences
in intracellular iodine content between the time points 2 or 5 min and the time
points 15 or 30 min. Vmax was twice as high for T-PS2 thyrocytes as for NT. B,
Steady-state uptake of NaI after incubation for 30 min. At any given
concentration of NaI, the intracellular iodide uptake by T-PS2 thyrocytes (black
bars) was twice as high as by NT (white bars). In both cell lines, coincubation
with 40 M NaClO4 blocked the iodide uptake (striped bars). C, Efflux of iodide
into the culture medium expressed as a percentage of the amount obtained at
time 0 after the steady-state uptake using 20 M NaI. NT thyrocytes released all
radioactive iodine to the medium after 15 min of initial washing. T-PS2 released
the radioactive iodine much more slowly, so that after 15 min, 40% still
remained inside the cells (P  0.01). Efflux stopped at 25 min, but the residual
amount inside the cell at that time was significantly higher in T-PS2 cells (black
bars) than in NT cells (white bars).
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normal levels of serum FT3. D1 and D2 will increase the intra-
thyroidal conversion of T4 into T3, andMCT8will maintain the
transport of thyroid hormones across thyrocytes. Interestingly,
the proposita’s L-thyroxine requirements were increased after
thyroidectomy due to loss of the thyroid as a source of T3. A
transient increase in serum TSH in response to low thyroid hor-
mone synthesis is a straightforward explanation for goiter de-
velopment in PS patients, although other
mechanisms could be involved. T-PS2 cells
showed increased iodide retention leading
to a steady intracellular iodide concentra-
tion. This finding suggests that intracellular
accumulation of iodide may occur in thyro-
cytes of PS patients with adequate iodine in-
take, and this could have a role in the func-
tional changes seen in diseased Pendred
thyrocytes. High dietary iodine intake pro-
motes goiter in humans (33), and although
the mechanisms are not clearly defined, the
Wolff-Chaikoff effect seems to play a role.
However, a direct stimulating action of io-
dine on thyrocyte proliferation is also pos-
sible. Very high NaI concentrations (10–50
mM) over several days inhibited the prolif-
eration of cultured rat FRTL-5 thyrocytes
(34), but this was probably a toxic effect. In
contrast, physiological concentrations (1
M KI, equivalent to 150 g/liter) stimu-
lated basal and epidermal growth factor-in-
duced proliferation in primary cultures of
porcine follicles (35, 36) through down-reg-
ulation of intracellular cAMP levels.
Family B’s clinical phenotype is compli-
cated by the finding of deafness with and
without SLC26A4 mutations. Also, ho-
mozygotes for c.416–1G3A have congen-
ital deafness, but not all have goiter. In fact,
neither goiter nor thyroid hormone abnor-
malities were found in the father of the pro-
positus, homozygous for c.416–1G3A. A
similar situation has been recently reported
in deaf people homozygous or compound
heterozygous for mutations in SLC26A4
(5). Absence of goiter and the mild thyroid
organification defect in the propositus’ fa-
ther suggests that iodine can cross the apical
border of thyroid cells. This can be ex-
plained by alternative splicing of the mu-
tatedmRNA,maintaining a limited amount
of normal transcript.Alternatively, some io-
dine passage may occur through diffusion,
as in the basolateral transport when NIS is
absent, or another apical iodine transporter
may take on pendrin’s function (37). In fact,
studies in our T-PS2 thyrocytes showed that
intracellular iodidewasable to leave the cell,
although more slowly and less efficiently
than from normal NT thyrocytes.
The lack of apical pendrin immunoreactivity in the two pro-
positi suggests that pathogenesis in our patientswas due not only
to functional impairment of pendrin but also to defective plasma
membrane targeting (38, 39): T-PS2 thyrocytes did not express
enough mature pendrin, as indicated by Western blotting and
immunofluorescence, although some mature protein was pro-
FIG. 6. Pendred thyrocytes quickly reach equilibrium for iodide uptake and progressively accumulate
intracellular iodide. A–D, Intracellular iodide uptake by thyrocytes incubated with different NaI
concentrations, at different times of incubation. Although at short incubation times (30 sec, A), the curves
were similar for both lines, at 5 min (B), T-PS2 thyrocytes reached equilibrium with Km  22  4.8 M,
similar to the Michaelis-Menten constant at equilibrium for iodide uptake by NIS (Km around 30–40 M). In
contrast, NT showed Km  81  4.2 M, far above equilibrium. Similar behavior was maintained at 30 min
(C), and at 1 h (D), NT thyrocytes finally reached equilibrium (Km  40.3  4.4 M). Except at very short
incubation times (30 sec), when Vmax was higher in NT cells, Vmax was about twice as high in T-PS2
thyrocytes at any given time. This result suggests that initially only the NIS transporter is working in NT, as
in T-PS2, but that after a few seconds pendrin starts to work in NT, and equilibrium is reached later.
J Clin Endocrinol Metab, January 2008, 93(1):267–277 jcem.endojournals.org 275
 by on June 7, 2010 jcem.endojournals.orgDownloaded from 
duced by alternative splicing. T-PS2 cells also showed Golgi im-
munofluorescence, indicating retention of severely truncated
proteins inside Golgi structures, as reported for other pendrin
mutants in transfection studies (38, 39). Interestingly, T-FA6
cells overexpress mature pendrin, although it seems to be re-
tained intracellularly, a finding that could be important in the
pathophysiology of cold adenomas.
In conclusion, we have described two families with PS from
Galicia. The founder mutation c.279delT was detected in both
families. A novel mutation, c.416–1G3A, affecting SLC26A4
splicing, was also found; absence of goiter in subjects homozy-
gous for this mutation could be explained by incomplete pen-
etrance. Someaffected subjects have goiterwithnormalTSHand
normal thyroid hormones or hypothyroxinemia. An increase in
D1 andD2 expression and activity and inMCT8 expressionwas
found in thyroid tissue of the proposita of family A. These
changes are adaptive responses to maintain a normal T3 supply
at the expense of T4. No pendrin immunoreactivity was seen at
the luminal border of follicles in the propositi’s thyroid glands,
and T-PS2 thyrocytes showed pendrin retention in Golgi struc-
tures, indicating thatmutations affect targeting of pendrin to the
plasma membrane. Pendred-affected thyrocytes showed low
iodide efflux and consequent accumulation, confirming the im-
portance of pendrin as an iodide transporter.
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